CerS4 knockdown partially reversed drug resistance in MCF-7/ADR cells treated with doxorubicin, paclitaxel, or tamoxifen (Fig. 6C–E), implying a critical role for CerS4 in the acquisition of MDR in breast cancer. Here, CERS4 is linked to breast carcinoma.